Earnings summaries and quarterly performance for Sonendo.
Research analysts who have asked questions during Sonendo earnings calls.
Jonathan Block
Stifel Financial Corp.
2 questions for SONX
Also covers: ALGN, COO, CUTR +11 more
Jason Bednar
Piper Sandler Companies
1 question for SONX
Also covers: ALGN, COO, EDAP +15 more
JF
Joseph Federico
Stifel
1 question for SONX
Also covers: CUTR
XW
Xuesong Wang
Morgan Stanley
1 question for SONX
Also covers: TMDX
Recent press releases and 8-K filings for SONX.
SonoThera to Present New Data at ESGCT 2025
SONX
New Projects/Investments
- SonoThera™ will present new data at the 32nd congress of the European Society of Gene and Cell Therapy (ESGCT) on Thursday, October 9, 2025, focusing on its proprietary ultrasound-mediated delivery (UMD) technology for treating Duchenne Muscular Dystrophy (DMD).
- The data demonstrates the UMD technology's ability to deliver genetic medicines, enabling full-length human dystrophin protein expression in skeletal, heart, and diaphragm muscle tissue in murine and non-human primate (NHP) models.
- Results show high levels of durable human dystrophin protein expression exceeding 50% of endogenous levels have been achieved in NHP.
- SonoThera's RIPPLE™ UMD approach is a nonviral, non-invasive, and redosable method designed to overcome current gene therapy delivery limitations, allowing for broad, highly targeted biodistribution of diverse genetic payloads without size restriction.
Oct 7, 2025, 11:30 AM
Quarterly earnings call transcripts for Sonendo.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more